Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$8.23 USD
+0.28 (3.52%)
Updated May 24, 2024 03:59 PM ET
After-Market: $8.23 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MNMD 8.23 +0.28(3.52%)
Will MNMD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MNMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNMD
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
MNMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock
MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
Other News for MNMD
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
The Time Traveler’s Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
Jim Cramer: This Industrial Company Is 'Absolutely Terrific', Recommends Buying Modine Manufacturing
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week